Phase II proof of concept trial of MDGN 201 (sustained erythropoietin therapy using the Biopump technology platform) in patients with beta thalassaemia intermedia.
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2014
Price : $35 *
At a glance
- Drugs MDGN 201 (Primary)
- Indications Beta-thalassaemia
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 24 Oct 2014 New trial record
- 15 Oct 2014 Initial results are expected in the second half of 2015, according to a Medgenics media release.